CO2021003713A2 - Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 - Google Patents
Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3Info
- Publication number
- CO2021003713A2 CO2021003713A2 CONC2021/0003713A CO2021003713A CO2021003713A2 CO 2021003713 A2 CO2021003713 A2 CO 2021003713A2 CO 2021003713 A CO2021003713 A CO 2021003713A CO 2021003713 A2 CO2021003713 A2 CO 2021003713A2
- Authority
- CO
- Colombia
- Prior art keywords
- methods
- disease
- aging
- compositions
- treating
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Inorganic Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862737017P | 2018-09-26 | 2018-09-26 | |
| PCT/US2019/052995 WO2020069008A1 (en) | 2018-09-26 | 2019-09-25 | Methods and compositions for treating aging-associated impairments using ccr3-inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2021003713A2 true CO2021003713A2 (es) | 2021-04-08 |
Family
ID=69953286
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2021/0003713A CO2021003713A2 (es) | 2018-09-26 | 2021-03-24 | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 |
Country Status (16)
| Country | Link |
|---|---|
| EP (1) | EP3856195A4 (de) |
| JP (1) | JP7528065B2 (de) |
| KR (1) | KR20210065950A (de) |
| CN (1) | CN112789044A (de) |
| AU (1) | AU2019346456A1 (de) |
| BR (1) | BR112021004938A2 (de) |
| CA (1) | CA3111433A1 (de) |
| CL (1) | CL2021000724A1 (de) |
| CO (1) | CO2021003713A2 (de) |
| EA (1) | EA202190463A1 (de) |
| IL (1) | IL281578A (de) |
| MA (1) | MA53743A (de) |
| MX (1) | MX2021002967A (de) |
| SG (1) | SG11202102105VA (de) |
| TW (1) | TW202027752A (de) |
| WO (1) | WO2020069008A1 (de) |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200538098A (en) * | 2004-03-22 | 2005-12-01 | Astrazeneca Ab | Therapeutic agents |
| EP1996551A2 (de) * | 2006-03-07 | 2008-12-03 | AstraZeneca AB | Piperidinderivate, verfahren zu ihrer herstellung, ihre verwendung als therapeutische mittel und pharmazeutische zusammensetzungen, die sie enthalten |
| US8278302B2 (en) | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
| BRPI1014669A2 (pt) | 2009-04-22 | 2017-07-18 | Axikin Pharmaceuticals Inc | antagonistas ccr3 de arilsulfonamida 2,5-dissubstituída |
| US20160208011A1 (en) * | 2010-01-28 | 2016-07-21 | The Board Of Trustees Of The Leland Stanford Junior University | Ccr3 modulation in the treatment of aging-associated impairments, and compositions for practicing the same |
| UA109290C2 (uk) * | 2010-10-07 | 2015-08-10 | Спільні кристали і солі інгібіторів ccr3 | |
| US20130261153A1 (en) * | 2012-04-03 | 2013-10-03 | Boehringer Ingelheim International Gmbh | Use of ccr3-inhibitors |
| US10213421B2 (en) * | 2012-04-04 | 2019-02-26 | Alkahest, Inc. | Pharmaceutical formulations comprising CCR3 antagonists |
| UA125658C2 (uk) * | 2017-04-05 | 2022-05-11 | Алкахест Інк. | Спосіб та композиція для лікування захворювання, пов'язаного з сітківкою ока, з використанням інгібітора ccr3 |
| BR112019020798A2 (pt) * | 2017-04-05 | 2020-04-28 | Alkahest Inc | métodos e composições para tratamento de danos associados ao envelhecimento usando inibidores de ccr3 |
-
2019
- 2019-09-25 MA MA053743A patent/MA53743A/fr unknown
- 2019-09-25 KR KR1020217008493A patent/KR20210065950A/ko unknown
- 2019-09-25 EA EA202190463A patent/EA202190463A1/ru unknown
- 2019-09-25 EP EP19867321.2A patent/EP3856195A4/de active Pending
- 2019-09-25 JP JP2021517342A patent/JP7528065B2/ja active Active
- 2019-09-25 SG SG11202102105VA patent/SG11202102105VA/en unknown
- 2019-09-25 CN CN201980063258.7A patent/CN112789044A/zh active Pending
- 2019-09-25 AU AU2019346456A patent/AU2019346456A1/en not_active Abandoned
- 2019-09-25 BR BR112021004938-0A patent/BR112021004938A2/pt not_active Application Discontinuation
- 2019-09-25 WO PCT/US2019/052995 patent/WO2020069008A1/en active Application Filing
- 2019-09-25 MX MX2021002967A patent/MX2021002967A/es unknown
- 2019-09-25 CA CA3111433A patent/CA3111433A1/en active Pending
- 2019-09-26 TW TW108134938A patent/TW202027752A/zh unknown
-
2021
- 2021-03-17 IL IL281578A patent/IL281578A/en unknown
- 2021-03-23 CL CL2021000724A patent/CL2021000724A1/es unknown
- 2021-03-24 CO CONC2021/0003713A patent/CO2021003713A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MA53743A (fr) | 2022-01-05 |
| CN112789044A (zh) | 2021-05-11 |
| CA3111433A1 (en) | 2020-04-02 |
| TW202027752A (zh) | 2020-08-01 |
| WO2020069008A1 (en) | 2020-04-02 |
| CL2021000724A1 (es) | 2021-10-15 |
| AU2019346456A1 (en) | 2021-04-15 |
| EP3856195A4 (de) | 2022-06-22 |
| MX2021002967A (es) | 2021-08-11 |
| JP7528065B2 (ja) | 2024-08-05 |
| BR112021004938A2 (pt) | 2021-06-01 |
| IL281578A (en) | 2021-05-31 |
| KR20210065950A (ko) | 2021-06-04 |
| SG11202102105VA (en) | 2021-04-29 |
| EP3856195A1 (de) | 2021-08-04 |
| JP2022502441A (ja) | 2022-01-11 |
| EA202190463A1 (ru) | 2021-06-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019012164A2 (es) | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 | |
| MX2022004102A (es) | Composiciones de oligonucleotidos y metodos de uso de las mismas. | |
| UY37174A (es) | Un compuesto heterocíclico que tiene una acción inhibidora de monoacilglicerol lipasa | |
| CL2019000787A1 (es) | Métodos para tratar trastornos mitocondriales y metabólicos. | |
| DOP2017000118A (es) | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 | |
| MY168643A (en) | Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism | |
| DOP2017000117A (es) | 2-amino-6-(difluorometil)- 5,5-difluoro-6-fenil-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 | |
| ECSP20042640A (es) | Derivados de indol 1, 3, 4, 5-tetrahidro-2h-pirido [4,3-b] para el tratamiento, alivio o prevención de trastornos asociados con agregados de tau como la enfermedad de alzheimer | |
| PH12019501371A1 (en) | PYRIMIDINE TRICYCLIC ENONE DERIVATIVES FOR INHIBITION OF RORy AND OTHERS USES | |
| CR20160394A (es) | Heteroaril amidas como inhibidores de agregación de proteína | |
| BR112018006445A2 (pt) | métodos para tratar distrofia muscular | |
| CL2020000070A1 (es) | Agentes, usos y métodos para el tratamiento. | |
| BR112018013084A2 (pt) | tratamentos de combinação compreendendo a administração de imidazopirazinonas | |
| WO2020058979A3 (en) | Methods of treating amyotrophic lateral sclerosis | |
| BR112017016378A2 (pt) | composições da pró-droga de fumarato de monometila | |
| WO2021100029A3 (en) | Prodrugs of fulvestrant | |
| CO2021003713A2 (es) | Métodos y composiciones para tratar deterioros asociados con el envejecimiento usando inhibidores de ccr3 | |
| WO2020117031A3 (en) | Composition and method for inhibiting amyloid beta accumulation and/or aggregation | |
| PE20220384A1 (es) | Composiciones y metodos de oximetazolina para el tratamiento de trastornos oculares | |
| EA201991753A1 (ru) | Алкоксибисгетероарильные производные в качестве модуляторов агрегации белков | |
| EA201890769A1 (ru) | Производные 2,3,4,5-тетрагидропиридин-6-амина | |
| JP1724081S (ja) | 保護眼鏡 | |
| JP1724082S (ja) | 保護眼鏡 | |
| MY195340A (en) | Compositions for Preventing or Treating Dry Eye | |
| MX2020009429A (es) | Una composicion sanitizante. |